News | February 22, 2022
Asahi Kasei to build new production unit for membrane virus filters in Japan
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
Evonik invests in start-up to improve patient recovery after open-chest surgery
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Subscribe To Our Newsletter & Stay Updated
